2. Academic Validation
  3. Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma

Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma

  • Eur Respir J. 2023 Mar 9;61(3):2201193. doi: 10.1183/13993003.01193-2022.
Gail M Gauvreau 1 2,  Jens M Hohlfeld 3 2,  J Mark FitzGerald 4 2,  Louis-Philippe Boulet 5,  Donald W Cockcroft 6,  Beth E Davis 6,  Stephanie Korn 7,  Oliver Kornmann 8,  Richard Leigh 9,  Irvin Mayers 10,  Henrik Watz 11,  Sarah S Grant 12,  Monish Jain 12,  Maciej Cabanski 12,  Peter E Pertel 12,  Ieuan Jones 13,  Jean R Lecot 13,  Hui Cao 14,  Paul M O'Byrne 15
Affiliations

Affiliations

  • 1 Department of Medicine, McMaster University, Hamilton, ON, Canada gauvreau@mcmaster.ca.
  • 2 These authors contributed equally to this work.
  • 3 Fraunhofer Institute for Toxicology and Experimental Medicine and Hannover Medical School, Hannover, Germany.
  • 4 Centre for Lung Health, University of British Columbia, Vancouver, BC, Canada.
  • 5 Québec Heart and Lung Institute, Laval University, Québec, QC, Canada.
  • 6 Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
  • 7 IKF Pneumologie Mainz and Thoraxklinik, Heidelberg, Germany.
  • 8 IKF Pneumologie Frankfurt, Clinical Research Centre Respiratory Diseases, Frankfurt, Germany.
  • 9 Department of Medicine, Cumming School of Medicine, Calgary, AB, Canada.
  • 10 Division of Pulmonary Medicine, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
  • 11 Pulmonary Research Institute at Lungen Clinic Grosshansdorf, Airway Research Centre North (ARCN), German Centre for Lung Research (DZL), Grosshansdorf, Germany.
  • 12 Novartis Institutes of Biomedical Research, Cambridge, MA, USA.
  • 13 Novartis Pharma AG, Basel, Switzerland.
  • 14 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • 15 Department of Medicine, McMaster University, Hamilton, ON, Canada.
PMID: 36822634 DOI: 10.1183/13993003.01193-2022
Abstract

Background: Thymic stromal lymphopoietin (TSLP) is a key upstream regulator driving allergic inflammatory responses. We evaluated the efficacy and safety of ecleralimab, a potent inhaled neutralising antibody fragment against human TSLP, using allergen inhalation challenge (AIC) in subjects with mild atopic asthma.

Methods: This was a 12-week, randomised, double-blind, placebo-controlled, parallel-design, multicentre allergen bronchoprovocation study conducted at 10 centres across Canada and Germany. Subjects aged 18-60 years with stable mild atopic asthma were randomised (1:1) to receive 4 mg once-daily inhaled ecleralimab or placebo. Primary end-points were the allergen-induced change in forced expiratory volume in 1 s (FEV1) during the late asthmatic response (LAR) measured by area under the curve (AUC3-7h) and maximum percentage decrease (LAR%) on day 84, and the safety of ecleralimab. Allergen-induced early asthmatic response (EAR), sputum eosinophils and fractional exhaled nitric oxide (F ENO) were secondary and exploratory end-points.

Results: 28 subjects were randomised to ecleralimab (n=15) or placebo (n=13). On day 84, ecleralimab significantly attenuated LAR AUC3-7h by 64% (p=0.008), LAR% by 48% (p=0.029), and allergen-induced sputum eosinophils by 64% at 7 h (p=0.011) and by 52% at 24 h (p=0.047) post-challenge. Ecleralimab also numerically reduced EAR AUC0-2h (p=0.097) and EAR% (p=0.105). F ENO levels were significantly reduced from baseline throughout the study (p<0.05), except at 24 h post-allergen (day 43 and day 85). Overall, ecleralimab was safe and well tolerated.

Conclusion: Ecleralimab significantly attenuated allergen-induced bronchoconstriction and airway inflammation, and was safe in subjects with mild atopic asthma.

Figures
Products